Physician profile
Janet Haley
NPI 1912487786
$4,120.86
in general payments reported to CMS, 2019-2025
27 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $468 · 2023: $628 · 2024: $1,039 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,708 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,707.76 |
| Education | $105.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $906.66 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $657.77 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $475.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $245.70 | 2021-2025 | |
| Incyte Corporation | $204.61 | 2021-2025 | Opzelura |
| Ucb, INC. | $188.27 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $185.83 | 2023-2024 | Vtama |
| Pfizer INC. | $168.31 | 2021-2025 | |
| Organon LLC | $163.56 | 2025 | Vtama |
| Leo Pharma INC. | $149.82 | 2021-2024 | Adbry |
| Amgen INC. | $103.08 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $88.25 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $70.98 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $67.53 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $63.50 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $57.51 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $56.89 | 2021-2025 | |
| Revance Therapeutics, INC. | $53.14 | 2025 | Daxxify |
| Janssen Biotech, INC. | $38.71 | 2021 | |
| Botanix Sb INC | $35.57 | 2025 | Sofdra |
| Springworks Therapeutics, INC. | $30.63 | 2025 | Gomekli |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.27 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.17 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.89 | 2024 | Spevigo |
| Lnhc, INC | $18.25 | 2025 | Zelsuvmi |
| Almirall LLC | $13.25 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $12.79 | 2023 | Hemangeol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Haley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.